Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2021-01-26 17:20:03
Reporting Period:
Accepted Time:
2021-01-26 17:20:03
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1668243 Urogen Pharma Ltd. URGN Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1763581 Mark Schoenberg 400 Alexander Park Drive
Princeton NJ 08540
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-01-26 208 $0.00 19,931 No 4 M Direct
Ordinary Shares Disposition 2021-01-26 100 $22.12 19,831 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Stock Units Disposition 2021-01-26 208 $0.00 208 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
834 No 4 M Direct
  1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
  2. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
  3. The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 2,500 ordinary shares. 33.33% of the RSUsvested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.